Identification

Name
Fosinopril
Accession Number
DB00492  (APRD00526)
Type
Small Molecule
Groups
Approved
Description

Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Structure
Thumb
Synonyms
  • Fosenopril
Product Ingredients
IngredientUNIICASInChI Key
Fosinopril sodiumNW2RTH6T2N88889-14-9TVTJZMHAIQQZTL-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FosinoprilTablet10 mgOralSanis Health Inc2017-04-11Not applicableCanada
FosinoprilTablet20 mgOralSanis Health Inc2017-04-11Not applicableCanada
Fosinopril TabletsTablet20 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Fosinopril TabletsTablet10 mgOralRanbaxy Inc.Not applicableNot applicableCanada
Fosinopril-10Tablet10 mgOralPro Doc Limitee2008-10-23Not applicableCanada
Fosinopril-20Tablet20 mgOralPro Doc Limitee2008-10-23Not applicableCanada
Monopril Tab 10mgTablet10 mgOralBristol Myers Squibb1992-12-312013-06-17Canada
Monopril Tab 20mgTablet20 mgOralBristol Myers Squibb1992-12-312013-06-17Canada
Ratio FosinoprilTablet20 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-02-082008-08-01Canada
Ratio FosinoprilTablet10 mgOralRatiopharm Inc Division Of Teva Canada Limited2006-02-082008-08-01Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-fosinoprilTablet10 mgOralApotex Corporation2005-04-27Not applicableCanada
Apo-fosinoprilTablet20 mgOralApotex Corporation2005-04-27Not applicableCanada
Ava-fosinoprilTablet20 mgOralAvanstra Inc2011-11-282014-08-21Canada
Ava-fosinoprilTablet10 mgOralAvanstra Inc2011-11-282014-08-21Canada
FOSINOPRIL NaTablet10 mg/1OralApotex Corporation2005-05-182017-02-24Us
FOSINOPRIL NaTablet40 mg/1OralApotex Corporation2005-05-182017-02-24Us60505 2512 02 nlmimage10 ee3f775b
FOSINOPRIL NaTablet20 mg/1OralApotex Corporation2005-05-182017-02-24Us
Fosinopril SodiumTablet10 mg/1OralPhysicians Total Care, Inc.2004-05-18Not applicableUs
Fosinopril SodiumTablet10 mg/1Oralbryant ranch prepack2007-09-17Not applicableUs31722 0200 90 nlmimage10 173b8b8c
Fosinopril SodiumTablet40 mg/1Oralbryant ranch prepack2016-06-16Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Fosinopril Sodium and HydrochlorothiazideFosinopril sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralGlenmark Pharmaceuticals Inc.,Usa2009-07-09Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralRising Health, Llc2009-07-09Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralHeritage2011-11-15Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralRanbaxy Inc.2004-12-20Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralPhysicians Total Care, Inc.2005-07-06Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralbryant ranch prepack2009-07-09Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralAurobindo Pharma2009-07-09Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril sodium (10 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralRanbaxy Inc.2004-12-20Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralEon Labs, Inc.2005-09-28Not applicableUs
Fosinopril Sodium and HydrochlorothiazideFosinopril sodium (20 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralHeritage2011-11-15Not applicableUs
International/Other Brands
Acecor (SPA (Czech Republic)) / Monopril (Bristol-Myers Squibb) / Staril (BMS (United Kingdom))
Categories
UNII
R43D2573WO
CAS number
98048-97-6
Weight
Average: 563.672
Monoisotopic: 563.301189823
Chemical Formula
C30H46NO7P
InChI Key
BIDNLKIUORFRQP-XYGFDPSESA-N
InChI
InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30+,39-/m1/s1
IUPAC Name
(2S,4S)-4-cyclohexyl-1-{2-[(R)-[(1S)-2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl]acetyl}pyrrolidine-2-carboxylic acid
SMILES
CCC(=O)O[C@@H](O[P@](=O)(CCCCC1=CC=CC=C1)CC(=O)N1C[C@@H](C[C@H]1C(O)=O)C1CCCCC1)C(C)C

Pharmacology

Indication

For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.

Associated Conditions
Pharmacodynamics

Following oral administration, fosinopril is rapidly and completely hydrolyzed to its principle active metabolite, fosinoprilat. Hydrolysis is thought to occur in the gastrointestinal mucosa and liver. Fosinoprilat is a competitive inhibitor of ACE, a peptidyl dipeptidase that is part of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may further sustain the effects of fosinoprilat by causing increased vasodilation and decreased blood pressure.

Mechanism of action

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Fosinoprilat, the active metabolite of fosinopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Fosinoprilat also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
Absorption

Average absolute absorption is 36%. The primary site of absorption is the proximal small intestine (duodenum/jejunum). Food slows the rate of absorption with no effect on the extent of absorption.

Volume of distribution
Not Available
Protein binding

Fosinoprilat is ≥95% protein bound

Metabolism

Since fosinoprilat is not biotransformed after intravenous administration, fosinopril, not fosinoprilat, appears to be the precursor for the glucuronide and p-hydroxy metabolites.

Route of elimination

After oral administration of radiolabeled fosinopril, approximately half of the absorbed dose is excreted in the urine and the remainder is excreted in the feces.

Half life

12 hours

Clearance
  • 26 - 39 mL/min [healthy]
Toxicity

Human overdoses of fosinopril have not been reported, but the most common manifestation of human fosinopril overdosage is likely to be hypotension. Oral doses of fosinopril at 2600 mg/kg in rats were associated with significant lethality. The most common adverse effects include dizzines, cough, fatigue, and headache.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Fosinopril Metabolism PathwayDrug metabolism
Fosinopril Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololFosinopril may increase the hypotensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Fosinopril.Approved, Investigational
AcemetacinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Acemetacin is combined with Fosinopril.Approved, Experimental, Investigational
Acetylsalicylic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Acetylsalicylic acid is combined with Fosinopril.Approved, Vet Approved
Agrostis gigantea pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Agrostis gigantea pollen.Approved
Agrostis stolonifera pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Agrostis stolonifera pollen.Approved
AlclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alclofenac is combined with Fosinopril.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Fosinopril.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Fosinopril.Approved, Investigational
AliskirenThe risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Fosinopril.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Fosinopril.Approved
AlmasilateAlmasilate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Alminoprofen is combined with Fosinopril.Experimental
AlogliptinThe risk or severity of angioedema can be increased when Alogliptin is combined with Fosinopril.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AloxiprinThe risk or severity of renal failure can be increased when Aloxiprin is combined with Fosinopril.Experimental
AlprenololFosinopril may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium phosphateAluminium phosphate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmbrisentanFosinopril may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AMG-222The risk or severity of angioedema can be increased when AMG-222 is combined with Fosinopril.Investigational
AmifostineFosinopril may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of hyperkalemia can be increased when Amiloride is combined with Fosinopril.Approved
AminophenazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aminophenazone is combined with Fosinopril.Approved, Withdrawn
Aminosalicylic AcidThe risk or severity of renal failure can be increased when Aminosalicylic Acid is combined with Fosinopril.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Fosinopril.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Fosinopril.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Fosinopril.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Fosinopril.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Fosinopril is combined with Amyl Nitrite.Approved
AnagliptinThe risk or severity of angioedema can be increased when Anagliptin is combined with Fosinopril.Investigational
AnisodamineThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Anisodamine.Investigational
Anthoxanthum odoratum pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Anthoxanthum odoratum pollen.Approved
AntipyrineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antipyrine is combined with Fosinopril.Approved, Investigational
AntrafenineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antrafenine is combined with Fosinopril.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Fosinopril.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Apraclonidine.Approved
AprotininAprotinin may decrease the antihypertensive activities of Fosinopril.Approved, Investigational, Withdrawn
ArdeparinThe risk or severity of hyperkalemia can be increased when Ardeparin is combined with Fosinopril.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Fosinopril.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fosinopril.Investigational
Arrhenatherum elatius pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Arrhenatherum elatius pollen.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Fosinopril.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Fosinopril.Approved
AvanafilAvanafil may increase the antihypertensive activities of Fosinopril.Approved
AzapropazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azapropazone is combined with Fosinopril.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Fosinopril is combined with Azathioprine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Fosinopril.Approved, Investigational
AzosemideAzosemide may increase the hypotensive activities of Fosinopril.Investigational
BalsalazideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Balsalazide is combined with Fosinopril.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Fosinopril.Experimental
BarbitalBarbital may increase the hypotensive activities of Fosinopril.Illicit
BarnidipineFosinopril may increase the antihypertensive activities of Barnidipine.Approved
BefunololThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Befunolol.Experimental
BemiparinThe risk or severity of hyperkalemia can be increased when Bemiparin is combined with Fosinopril.Approved, Investigational
BenazeprilFosinopril may increase the hypotensive activities of Benazepril.Approved, Investigational
BenazeprilatFosinopril may increase the hypotensive activities of Benazeprilat.Experimental
BendazacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bendazac is combined with Fosinopril.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Fosinopril.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Fosinopril.Withdrawn
BenorilateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benorilate is combined with Fosinopril.Experimental
BenoxaprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benoxaprofen is combined with Fosinopril.Withdrawn
BenzthiazideThe risk or severity of hypotension can be increased when Benzthiazide is combined with Fosinopril.Approved
BenzydamineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benzydamine is combined with Fosinopril.Approved
BepridilFosinopril may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Fosinopril.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Fosinopril.Approved
BevantololFosinopril may increase the hypotensive activities of Bevantolol.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Fosinopril.Experimental
BimatoprostFosinopril may increase the hypotensive activities of Bimatoprost.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololFosinopril may increase the hypotensive activities of Bisoprolol.Approved
BopindololThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Bopindolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Fosinopril.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Fosinopril.Approved, Investigational
Bouteloua gracilis pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bouteloua gracilis pollen.Approved
BQ-123Fosinopril may increase the hypotensive activities of BQ-123.Investigational
BretyliumFosinopril may increase the hypotensive activities of Bretylium.Approved
BromfenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bromfenac is combined with Fosinopril.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Fosinopril.Approved, Investigational
Bromus secalinus pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Bromus secalinus pollen.Approved
BucindololThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Bucindolol.Investigational
BufexamacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bufexamac is combined with Fosinopril.Approved, Experimental
BufuralolThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Bumadizone is combined with Fosinopril.Experimental
BumetanideBumetanide may increase the hypotensive activities of Fosinopril.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Fosinopril.Approved, Investigational
BupranololFosinopril may increase the hypotensive activities of Bupranolol.Approved
CadralazineCadralazine may increase the hypotensive activities of Fosinopril.Experimental
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Fosinopril.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Fosinopril.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Fosinopril.Approved
CandoxatrilFosinopril may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilFosinopril may increase the hypotensive activities of Captopril.Approved
Carbaspirin calciumThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Carbaspirin calcium is combined with Fosinopril.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Fosinopril.Approved, Investigational
CarmegliptinThe risk or severity of angioedema can be increased when Carmegliptin is combined with Fosinopril.Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Fosinopril.Withdrawn
CarprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Carprofen is combined with Fosinopril.Approved, Vet Approved, Withdrawn
CarteololFosinopril may increase the hypotensive activities of Carteolol.Approved
CarvedilolFosinopril may increase the hypotensive activities of Carvedilol.Approved, Investigational
CelecoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Celecoxib is combined with Fosinopril.Approved, Investigational
CeliprololFosinopril may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinThe risk or severity of hyperkalemia can be increased when Certoparin is combined with Fosinopril.Approved, Investigational
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Fosinopril.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Fosinopril.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Fosinopril.Approved
Choline magnesium trisalicylateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Choline magnesium trisalicylate is combined with Fosinopril.Approved
CicletanineFosinopril may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilFosinopril may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Fosinopril.Approved, Investigational
CimicoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Cimicoxib is combined with Fosinopril.Investigational
CiprofloxacinThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Ciprofloxacin.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Fosinopril.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Fosinopril.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Fosinopril.Approved
ClonixinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Clonixin is combined with Fosinopril.Approved
CloranololFosinopril may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Fosinopril.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Fosinopril.Approved, Investigational
CryptenamineFosinopril may increase the hypotensive activities of Cryptenamine.Approved
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Fosinopril.Experimental
CyclosporineThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideFosinopril may increase the hypotensive activities of Cyclothiazide.Approved
Cynodon dactylon pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Cynodon dactylon pollen.Approved
Dactylis glomerata pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dactylis glomerata pollen.Approved
DalteparinThe risk or severity of hyperkalemia can be increased when Dalteparin is combined with Fosinopril.Approved
DanaparoidThe risk or severity of hyperkalemia can be increased when Danaparoid is combined with Fosinopril.Approved, Withdrawn
DapagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Fosinopril.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Fosinopril.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Fosinopril.Approved, Investigational
DelaprilFosinopril may increase the hypotensive activities of Delapril.Investigational
DersalazineThe risk or severity of renal failure can be increased when Dersalazine is combined with Fosinopril.Investigational
DeserpidineFosinopril may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Fosinopril.Approved
DexibuprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexibuprofen is combined with Fosinopril.Approved, Investigational
DexketoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexketoprofen is combined with Fosinopril.Approved, Investigational
DexlansoprazoleDexlansoprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dexmedetomidine.Approved, Vet Approved
DexniguldipineFosinopril may increase the hypotensive activities of Dexniguldipine.Experimental
DexrabeprazoleDexrabeprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DiazoxideDiazoxide may increase the hypotensive activities of Fosinopril.Approved
DiclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Fosinopril.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineFosinopril may increase the hypotensive activities of Diethylnorspermine.Investigational
DifenpiramideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Difenpiramide is combined with Fosinopril.Experimental
DiflunisalThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diflunisal is combined with Fosinopril.Approved, Investigational
DigoxinThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Digoxin.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Fosinopril.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Fosinopril.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dinutuximab.Approved, Investigational
DipyridamoleDipyridamole may increase the antihypertensive activities of Fosinopril.Approved
Distichlis spicata pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Distichlis spicata pollen.Approved
DorzolamideFosinopril may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Fosinopril.Approved
DrospirenoneFosinopril may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Droxicam is combined with Fosinopril.Withdrawn
DuloxetineFosinopril may increase the orthostatic hypotensive activities of Duloxetine.Approved
DutogliptinThe risk or severity of angioedema can be increased when Dutogliptin is combined with Fosinopril.Investigational
EfonidipineFosinopril may increase the hypotensive activities of Efonidipine.Approved, Investigational
Elymus repens pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Elymus repens pollen.Approved
EmpagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Empagliflozin is combined with Fosinopril.Approved
EnalaprilFosinopril may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatFosinopril may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Fosinopril.Experimental
EnoxaparinThe risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Fosinopril.Approved
EpanololFosinopril may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Epirizole is combined with Fosinopril.Approved
EpitizideThe risk or severity of hypotension can be increased when Epitizide is combined with Fosinopril.Experimental
EplerenoneEplerenone may increase the hyperkalemic activities of Fosinopril.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Fosinopril.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Fosinopril.Approved
ErtugliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Ertugliflozin is combined with Fosinopril.Approved, Investigational
EsatenololFosinopril may increase the hypotensive activities of Esatenolol.Experimental
EsmololFosinopril may increase the hypotensive activities of Esmolol.Approved
EsomeprazoleEsomeprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Fosinopril.Approved, Investigational
EthenzamideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ethenzamide is combined with Fosinopril.Experimental
EtodolacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etodolac is combined with Fosinopril.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etofenamate is combined with Fosinopril.Approved, Investigational
EtoricoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etoricoxib is combined with Fosinopril.Approved, Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Fosinopril.Approved
EvogliptinThe risk or severity of angioedema can be increased when Evogliptin is combined with Fosinopril.Investigational
FelbinacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Felbinac is combined with Fosinopril.Experimental
FelodipineFosinopril may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenbufen is combined with Fosinopril.Approved
FenoldopamFosinopril may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenoprofen is combined with Fosinopril.Approved
FentiazacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fentiazac is combined with Fosinopril.Experimental
FeprazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Feprazone is combined with Fosinopril.Experimental
Ferulic acidFosinopril may increase the hypotensive activities of Ferulic acid.Experimental
Festuca pratensis pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Festuca pratensis pollen.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Fosinopril.Approved, Investigational
FirocoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Firocoxib is combined with Fosinopril.Experimental, Vet Approved
FloctafenineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Floctafenine is combined with Fosinopril.Approved, Withdrawn
FluconazoleThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Fluconazole.Approved, Investigational
FlunixinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flunixin is combined with Fosinopril.Vet Approved
FlunoxaprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flunoxaprofen is combined with Fosinopril.Experimental
FlurbiprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flurbiprofen is combined with Fosinopril.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Fosinopril.Experimental
FosinoprilatFosinopril may increase the hypotensive activities of Fosinoprilat.Experimental
FostamatinibFostamatinib may increase the antihypertensive activities of Fosinopril.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Fosinopril.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
GemigliptinThe risk or severity of angioedema can be increased when Gemigliptin is combined with Fosinopril.Investigational
GosogliptinThe risk or severity of angioedema can be increased when Gosogliptin is combined with Fosinopril.Investigational
GuacetisalThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Guacetisal is combined with Fosinopril.Experimental
GuanabenzFosinopril may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Fosinopril.Approved
GuanazodineFosinopril may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineFosinopril may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Fosinopril.Approved, Investigational
GuanoclorFosinopril may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzFosinopril may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanFosinopril may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Fosinopril.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Fosinopril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Heparin.Approved, Investigational
HexamethoniumFosinopril may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Fosinopril.Approved
Holcus lanatus pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Holcus lanatus pollen.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Fosinopril.Experimental
HydralazineHydralazine may increase the hypotensive activities of Fosinopril.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Fosinopril.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Fosinopril.Approved, Investigational
HydrotalciteHydrotalcite can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
IbuprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Fosinopril.Approved
IbuproxamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuproxam is combined with Fosinopril.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Fosinopril.Approved, Investigational
IcosapentThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Icosapent is combined with Fosinopril.Approved, Nutraceutical
IloprostIloprost may increase the hypotensive activities of Fosinopril.Approved, Investigational
ImidaprilFosinopril may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Imidazole salicylate is combined with Fosinopril.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Fosinopril.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Fosinopril.Approved
IndenololFosinopril may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indobufen is combined with Fosinopril.Investigational
IndomethacinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Fosinopril.Approved, Investigational
IndoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indoprofen is combined with Fosinopril.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Fosinopril.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Fosinopril.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Fosinopril.Approved, Investigational
IronIron can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Fosinopril is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Fosinopril.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Fosinopril.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Isoxicam is combined with Fosinopril.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Fosinopril.Approved, Investigational
ItraconazoleThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Kebuzone is combined with Fosinopril.Experimental
KetanserinKetanserin may increase the hypotensive activities of Fosinopril.Investigational
KetoconazoleThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketoprofen is combined with Fosinopril.Approved, Vet Approved
KetorolacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketorolac is combined with Fosinopril.Approved
Koeleria macrantha pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Koeleria macrantha pollen.Approved
KRP-104The risk or severity of angioedema can be increased when KRP-104 is combined with Fosinopril.Investigational
LabetalolFosinopril may increase the hypotensive activities of Labetalol.Approved
LacidipineFosinopril may increase the hypotensive activities of Lacidipine.Approved, Investigational
LandiololThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Landiolol.Investigational
LansoprazoleLansoprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Lanthanum carbonateThe serum concentration of Fosinopril can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostFosinopril may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineFosinopril may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobetaxololThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Levobetaxolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Fosinopril is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Fosinopril.Approved, Investigational
LevodopaFosinopril may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Fosinopril.Approved, Investigational
LinagliptinThe risk or severity of angioedema can be increased when Linagliptin is combined with Fosinopril.Approved
LinezolidLinezolid may increase the hypotensive activities of Fosinopril.Approved, Investigational
LinsidomineFosinopril may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilFosinopril may increase the hypotensive activities of Lisinopril.Approved, Investigational
Lithium cationThe serum concentration of Lithium cation can be increased when it is combined with Fosinopril.Experimental
LofexidineFosinopril may increase the hypotensive activities of Lofexidine.Approved, Investigational
Lolium perenne pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lolium perenne pollen.Approved
Lolium perenne subsp. multiflorum pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Lolium perenne subsp. multiflorum pollen.Approved
LonazolacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lonazolac is combined with Fosinopril.Experimental
LornoxicamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lornoxicam is combined with Fosinopril.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Fosinopril.Approved
LoxoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Loxoprofen is combined with Fosinopril.Approved, Investigational
LumiracoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lumiracoxib is combined with Fosinopril.Approved, Investigational
MacitentanFosinopril may increase the hypotensive activities of Macitentan.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Magnesium salicylate is combined with Fosinopril.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineFosinopril may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mannitol.Approved, Investigational
Mannitol busulfanThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Mannitol busulfan.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Fosinopril.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Fosinopril.Approved, Investigational
Meclofenamic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meclofenamic acid is combined with Fosinopril.Approved, Vet Approved
Mefenamic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mefenamic acid is combined with Fosinopril.Approved
MeloxicamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meloxicam is combined with Fosinopril.Approved, Vet Approved
MepindololThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Mepindolol.Experimental
MesalazineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Fosinopril.Approved
MetamizoleThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Metamizole is combined with Fosinopril.Approved, Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Fosinopril.Approved
MethoserpidineFosinopril may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Fosinopril.Approved
Methyl salicylateThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Fosinopril.Approved, Vet Approved
MethyldopaFosinopril may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Fosinopril.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Fosinopril.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Fosinopril.Approved
MetipranololFosinopril may increase the hypotensive activities of Metipranolol.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Fosinopril.Approved
MetoprololMetoprolol may increase the hypotensive activities of Fosinopril.Approved, Investigational
MetyrosineFosinopril may increase the hypotensive activities of Metyrosine.Approved
MibefradilFosinopril may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MinaprineMinaprine may increase the hypotensive activities of Fosinopril.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Fosinopril.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Fosinopril.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Fosinopril.Approved, Investigational
MoexiprilFosinopril may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mofebutazone is combined with Fosinopril.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Fosinopril.Approved, Investigational
MorniflumateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Morniflumate is combined with Fosinopril.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Fosinopril.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Fosinopril.Approved, Investigational
MuzolimineFosinopril may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Fosinopril.Approved, Investigational
NabumetoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nabumetone is combined with Fosinopril.Approved
NadololFosinopril may increase the hypotensive activities of Nadolol.Approved
NadroparinThe risk or severity of hyperkalemia can be increased when Nadroparin is combined with Fosinopril.Approved, Investigational
NaftopidilFosinopril may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Fosinopril.Approved, Vet Approved
NebivololFosinopril may increase the hypotensive activities of Nebivolol.Approved, Investigational
NepafenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nepafenac is combined with Fosinopril.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Fosinopril.Withdrawn
NicardipineFosinopril may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Fosinopril.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nifedipine.Approved
NifenazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nifenazone is combined with Fosinopril.Experimental
Niflumic AcidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Niflumic Acid is combined with Fosinopril.Approved
NiguldipineFosinopril may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineFosinopril may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Fosinopril.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Fosinopril.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Fosinopril.Approved
NitrendipineFosinopril may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Fosinopril.Approved
NitroaspirinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nitroaspirin is combined with Fosinopril.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Fosinopril.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Fosinopril.Approved, Investigational
NS-398The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when NS-398 is combined with Fosinopril.Experimental
ObinutuzumabFosinopril may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Fosinopril.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Fosinopril.Approved, Investigational
OlsalazineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olsalazine is combined with Fosinopril.Approved
OmapatrilatFosinopril may increase the hypotensive activities of Omapatrilat.Investigational
OmarigliptinThe risk or severity of angioedema can be increased when Omarigliptin is combined with Fosinopril.Investigational
OmeprazoleOmeprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
OxaprozinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxaprozin is combined with Fosinopril.Approved
OxprenololFosinopril may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxyphenbutazone is combined with Fosinopril.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Fosinopril.Approved, Vet Approved
PantoprazolePantoprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PapaverineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Papaverine.Approved, Investigational
ParecoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Parecoxib is combined with Fosinopril.Approved
PargylinePargyline may increase the hypotensive activities of Fosinopril.Approved
ParnaparinThe risk or severity of hyperkalemia can be increased when Parnaparin is combined with Fosinopril.Approved, Investigational
Pascopyrum smithii pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Pascopyrum smithii pollen.Approved
Paspalum notatum pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Paspalum notatum pollen.Approved
Patent BlueThe risk or severity of anaphylaxis can be increased when Fosinopril is combined with Patent Blue.Approved
PenbutololFosinopril may increase the hypotensive activities of Penbutolol.Approved, Investigational
Penicillin G Acyl-SerineThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Penicillin G Acyl-Serine.Experimental
PentamidineThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Pentamidine.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Fosinopril.Approved, Investigational, Vet Approved
PentoliniumFosinopril may increase the hypotensive activities of Pentolinium.Approved
PerindoprilFosinopril may increase the hypotensive activities of Perindopril.Approved
PerindoprilatFosinopril may increase the hypotensive activities of Perindoprilat.Experimental
Phalaris arundinacea pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Phalaris arundinacea pollen.Approved
Phalaris minor pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Phalaris minor pollen.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Fosinopril.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Fosinopril.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Fosinopril.Approved, Investigational
PhenoxybenzamineFosinopril may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Fosinopril.Withdrawn
PhentolamineFosinopril may increase the hypotensive activities of Phentolamine.Approved
Phenyl aminosalicylateThe risk or severity of renal failure can be increased when Phenyl aminosalicylate is combined with Fosinopril.Approved
PhenylbutazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Phenylbutazone is combined with Fosinopril.Approved, Vet Approved
Phleum pratense pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Phleum pratense pollen.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Fosinopril.Approved
PindololFosinopril may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Fosinopril.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Fosinopril.Approved
PirlindolePirlindole may increase the hypotensive activities of Fosinopril.Approved
PiroxicamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Piroxicam is combined with Fosinopril.Approved, Investigational
PirprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Pirprofen is combined with Fosinopril.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Fosinopril.Withdrawn
Poa annua pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Poa annua pollen.Approved
Poa compressa pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Poa compressa pollen.Approved
Poa pratensis pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Poa pratensis pollen.Approved
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Fosinopril.Approved
Potassium acetateThe risk or severity of hyperkalemia can be increased when Potassium acetate is combined with Fosinopril.Approved, Investigational
Potassium bicarbonateThe risk or severity of hyperkalemia can be increased when Potassium bicarbonate is combined with Fosinopril.Approved
Potassium cationThe risk or severity of hyperkalemia can be increased when Potassium cation is combined with Fosinopril.Approved, Investigational
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Fosinopril.Approved, Withdrawn
Potassium CitrateThe risk or severity of hyperkalemia can be increased when Potassium Citrate is combined with Fosinopril.Approved, Investigational, Vet Approved
PractololFosinopril may increase the hypotensive activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Fosinopril.Approved, Investigational
PranoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Pranoprofen is combined with Fosinopril.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Fosinopril.Approved
PregabalinThe risk or severity of angioedema can be increased when Fosinopril is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
ProglumetacinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Proglumetacin is combined with Fosinopril.Experimental
PropacetamolThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Propacetamol is combined with Fosinopril.Approved, Investigational
PropafenoneThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Fosinopril.Approved, Investigational, Vet Approved
PropranololFosinopril may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Propyphenazone is combined with Fosinopril.Experimental
ProquazoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Proquazone is combined with Fosinopril.Experimental
QuetiapineThe risk or severity of adverse effects can be increased when Fosinopril is combined with Quetiapine.Approved
QuinaprilFosinopril may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinaprilatFosinopril may increase the hypotensive activities of Quinaprilat.Experimental
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Fosinopril.Approved
QuinineQuinine may increase the hypotensive activities of Fosinopril.Approved
RabeprazoleRabeprazole can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RamiprilRamipril may increase the hypotensive activities of Fosinopril.Approved
RamiprilatFosinopril may increase the hypotensive activities of Ramiprilat.Experimental
RasagilineRasagiline may increase the hypotensive activities of Fosinopril.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fosinopril.Approved
RemikirenRemikiren may increase the hypotensive activities of Fosinopril.Approved
RescinnamineFosinopril may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Fosinopril.Approved, Investigational
ReviparinThe risk or severity of hyperkalemia can be increased when Reviparin is combined with Fosinopril.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Fosinopril.Approved, Investigational
RiociguatFosinopril may increase the hypotensive activities of Riociguat.Approved
RisperidoneFosinopril may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabFosinopril may increase the hypotensive activities of Rituximab.Approved
RobenacoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Robenacoxib is combined with Fosinopril.Experimental, Vet Approved
RofecoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Rofecoxib is combined with Fosinopril.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Fosinopril.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Fosinopril.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Fosinopril.Approved
SacubitrilThe risk or severity of angioedema can be increased when Fosinopril is combined with Sacubitril.Approved
SafinamideSafinamide may increase the hypotensive activities of Fosinopril.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Fosinopril.Withdrawn
SalicylamideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylamide is combined with Fosinopril.Approved
Salicylic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Fosinopril.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salsalate is combined with Fosinopril.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Fosinopril.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Fosinopril.Investigational
SaxagliptinThe risk or severity of angioedema can be increased when Saxagliptin is combined with Fosinopril.Approved
SC-236The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when SC-236 is combined with Fosinopril.Experimental, Investigational
Secale cereale pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Secale cereale pollen.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Fosinopril.Approved, Investigational, Vet Approved
SelexipagFosinopril may increase the hypotensive activities of Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fosinopril.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Fosinopril.Approved, Investigational
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Fosinopril.Approved, Investigational
SitagliptinThe risk or severity of angioedema can be increased when Sitagliptin is combined with Fosinopril.Approved, Investigational
SitaxentanFosinopril may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Fosinopril is combined with Sodium aurothiomalate.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphate, monobasicThe risk or severity of nephrotoxicity can be increased when Fosinopril is combined with Sodium phosphate, monobasic.Approved
Sorghum bicolor subsp. drummondii pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sorghum bicolor subsp. drummondii pollen.Approved
Sorghum halepense pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sorghum halepense pollen.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Fosinopril.Approved
SpiraprilFosinopril may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of hyperkalemia can be increased when Spironolactone is combined with Fosinopril.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Fosinopril.Approved, Investigational
SuccinylcholineThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fosinopril.Approved, Investigational
SulfasalazineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Fosinopril.Approved
SulindacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Fosinopril.Approved, Investigational
SulodexideThe risk or severity of hyperkalemia can be increased when Sulodexide is combined with Fosinopril.Approved, Investigational
SuprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Suprofen is combined with Fosinopril.Approved, Withdrawn
SuxibuzoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Suxibuzone is combined with Fosinopril.Experimental
TacrolimusThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Fosinopril.Approved, Investigational
TalinololFosinopril may increase the hypotensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Talniflumate is combined with Fosinopril.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Fosinopril.Approved, Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Fosinopril.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Fosinopril.Approved, Investigational
TemocaprilFosinopril may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe risk or severity of angioedema can be increased when Temsirolimus is combined with Fosinopril.Approved
TeneligliptinThe risk or severity of angioedema can be increased when Teneligliptin is combined with Fosinopril.Investigational
TenidapThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenidap is combined with Fosinopril.Experimental
TenoxicamThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenoxicam is combined with Fosinopril.Approved
TepoxalinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tepoxalin is combined with Fosinopril.Vet Approved
TerazosinFosinopril may increase the hypotensive activities of Terazosin.Approved
TertatololThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Tertatolol.Experimental
TetrahydropalmatineFosinopril may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Fosinopril.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the antihypertensive activities of Fosinopril.Approved
ThiamylalThiamylal may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Fosinopril.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Fosinopril.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tiaprofenic acid is combined with Fosinopril.Approved
TicrynafenFosinopril may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololFosinopril may increase the hypotensive activities of Timolol.Approved
TinoridineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tinoridine is combined with Fosinopril.Investigational
TinzaparinThe risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Fosinopril.Approved
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Fosinopril.Approved, Investigational
TocopherylquinoneFosinopril may increase the hypotensive activities of Tocopherylquinone.Experimental, Investigational
TolazolineFosinopril may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Fosinopril.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Fosinopril.Approved, Investigational
TolmetinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolmetin is combined with Fosinopril.Approved
TolonidineFosinopril may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Fosinopril.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Fosinopril.Approved
TorasemideTorasemide may increase the hypotensive activities of Fosinopril.Approved
TrandolaprilFosinopril may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Fosinopril.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Fosinopril.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Fosinopril.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Fosinopril.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of hyperkalemia can be increased when Triamterene is combined with Fosinopril.Approved
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Fosinopril.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Fosinopril.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Fosinopril.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Fosinopril.Approved, Vet Approved
TrimethoprimThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Trimethoprim.Approved, Vet Approved
Trolamine salicylateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Fosinopril.Approved
UdenafilUdenafil may increase the antihypertensive activities of Fosinopril.Approved, Investigational
UnoprostoneFosinopril may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Fosinopril.Investigational
Urochloa mutica pollenThe risk or severity of adverse effects can be increased when Fosinopril is combined with Urochloa mutica pollen.Approved
ValdecoxibThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valdecoxib is combined with Fosinopril.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Fosinopril.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Fosinopril.Approved
VerapamilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Verapamil.Approved
VildagliptinThe risk or severity of angioedema can be increased when Vildagliptin is combined with Fosinopril.Approved, Investigational
VincamineFosinopril may increase the hypotensive activities of Vincamine.Experimental
XipamideFosinopril may increase the hypotensive activities of Xipamide.Experimental
YohimbineYohimbine may decrease the antihypertensive activities of Fosinopril.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zaltoprofen is combined with Fosinopril.Approved, Investigational
ZofenoprilFosinopril may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zomepirac is combined with Fosinopril.Withdrawn
Food Interactions
  • Do not take calcium, aluminum, magnesium or iron supplements, or antacids within 2 hours of taking this medication.
  • Fosinopril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
  • Herbs that may attenuate the antihypertensive effect of fosinopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of fosinopril.
  • Take without regard to meals.

References

Synthesis Reference

Sandra Gallego Pato, Antonio Palomo Coll, Francisco Palomo Nicolau, "Preparation of crystalline polymorphs of fosinopril sodium." U.S. Patent US20050010054, issued January 13, 2005.

US20050010054
General References
  1. David D, Jallad N, Germino FW, Willett MS, de Silva J, Weidner SM, Mills DJ: A Comparison of the Cough Profile of Fosinopril and Enalapril in Hypertensive Patients with a History of ACE Inhibitor-Associated Cough. Am J Ther. 1995 Oct;2(10):806-813. [PubMed:11854791]
  2. Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. [PubMed:11329095]
External Links
Human Metabolome Database
HMDB0014635
KEGG Drug
D00622
KEGG Compound
C07016
PubChem Compound
55891
PubChem Substance
46506495
ChemSpider
7875352
ChEBI
5163
ChEMBL
CHEMBL3039598
Therapeutic Targets Database
DAP000582
PharmGKB
PA449710
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Fosinopril
ATC Codes
C09AA09 — FosinoprilC09BA09 — Fosinopril and diuretics
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors
FDA label
Download (206 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedPreventionCardiovascular Disease (CVD) / Heart Diseases / High Blood Pressure (Hypertension)1
2CompletedTreatmentDiabetic Nephropathies1
3CompletedPreventionCardiovascular Disease (CVD) / Kidney Diseases / Microalbuminuria1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Induction of intra-operative hypotension1
4Not Yet RecruitingTreatmentChronic Kidney Disease (CKD)1
Not AvailableCompletedNot AvailableHealthy Volunteers4
Not AvailableCompletedTreatmentDiabetes Mellitus (DM) / Hypertension,Essential1
Not AvailableUnknown StatusTreatmentAngiotensin II Type 1 Receptor Blockers / Angiotensin-Converting Enzyme Inhibitors / Kidney Insufficiency, Chronic / Proteinuria1

Pharmacoeconomics

Manufacturers
  • Apotex inc etobicoke site
  • Invagen pharmaceuticals inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Watson laboratories inc florida
  • Bristol myers squibb co pharmaceutical research institute
Packagers
  • Apotex Inc.
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Blu Pharmaceuticals LLC
  • Bristol-Myers Squibb Co.
  • Cobalt Pharmaceuticals Inc.
  • Deca Pharmaceuticals LLC
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • Glenmark Generics Ltd.
  • InvaGen Pharmaceuticals Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Murfreesboro Pharmaceutical Nursing Supply
  • Neuman Distributors Inc.
  • Nucare Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Princeton Pharmaceutical Products Inc.
  • Ranbaxy Laboratories
  • Resource Optimization and Innovation LLC
  • Teva Pharmaceutical Industries Ltd.
  • Va Cmop Dallas
  • Watson Pharmaceuticals
Dosage forms
FormRouteStrength
TabletOral10 1/1
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral40 mg/1
TabletOral40 1/1
TabletOral
TabletOral10 mg
TabletOral20 mg
Prices
Unit descriptionCostUnit
Monopril HCT 10-12.5 mg tablet1.71USD tablet
Monopril 10 mg tablet1.68USD tablet
Monopril 40 mg tablet1.67USD tablet
Monopril 20 mg tablet1.62USD tablet
Fosinopril Sodium-HCTZ 10-12.5 mg tablet1.61USD tablet
Fosinopril Sodium-HCTZ 20-12.5 mg tablet1.61USD tablet
Fosinopril sodium 20 mg tablet1.25USD tablet
Fosinopril sodium 40 mg tablet1.25USD tablet
Fosinopril sodium 10 mg tablet1.21USD tablet
Monopril 20 mg Tablet1.1USD tablet
Monopril 10 mg Tablet0.91USD tablet
Apo-Fosinopril 20 mg Tablet0.61USD tablet
Fosinopril 20 mg Tablet0.61USD tablet
Jamp-Fosinopril 20 mg Tablet0.61USD tablet
Mylan-Fosinopril 20 mg Tablet0.61USD tablet
Novo-Fosinopril 20 mg Tablet0.61USD tablet
Ran-Fosinopril 20 mg Tablet0.61USD tablet
Apo-Fosinopril 10 mg Tablet0.51USD tablet
Fosinopril 10 mg Tablet0.51USD tablet
Jamp-Fosinopril 10 mg Tablet0.51USD tablet
Mylan-Fosinopril 10 mg Tablet0.51USD tablet
Novo-Fosinopril 10 mg Tablet0.51USD tablet
Ran-Fosinopril 10 mg Tablet0.51USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5006344No1993-01-102010-01-10Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)149-153 °CNot Available
water solubilityInsolubleNot Available
logP6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00101 mg/mLALOGPS
logP4.71ALOGPS
logP5.62ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)3.87ChemAxon
pKa (Strongest Basic)-4.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.21 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity149.12 m3·mol-1ChemAxon
Polarizability61.83 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9532
Blood Brain Barrier-0.667
Caco-2 permeable-0.6561
P-glycoprotein substrateSubstrate0.6165
P-glycoprotein inhibitor IInhibitor0.7161
P-glycoprotein inhibitor IINon-inhibitor0.6774
Renal organic cation transporterNon-inhibitor0.812
CYP450 2C9 substrateNon-substrate0.7028
CYP450 2D6 substrateNon-substrate0.8128
CYP450 3A4 substrateSubstrate0.6729
CYP450 1A2 substrateNon-inhibitor0.8913
CYP450 2C9 inhibitorNon-inhibitor0.7438
CYP450 2D6 inhibitorNon-inhibitor0.9004
CYP450 2C19 inhibitorNon-inhibitor0.5725
CYP450 3A4 inhibitorNon-inhibitor0.7303
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6376
Ames testNon AMES toxic0.7141
CarcinogenicityNon-carcinogens0.8025
BiodegradationNot ready biodegradable0.8102
Rat acute toxicity2.8211 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9534
hERG inhibition (predictor II)Non-inhibitor0.5918
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Ondetti MA: Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity. Circulation. 1988 Jun;77(6 Pt 2):I74-8. [PubMed:2836111]
  3. Piepho RW: Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2000 Oct 1;57 Suppl 1:S3-7. [PubMed:11030016]
  4. Sharma S, Deitchman D, Eni JS, Gelperin K, Ilgenfritz JP, Blumenthal M: The hemodynamic effects of long-term ACE inhibition with fosinopril in patients with heart failure. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9. [PubMed:11329095]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name
SLC15A1
Uniprot ID
P46059
Uniprot Name
Solute carrier family 15 member 1
Molecular Weight
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Peptide:proton symporter activity
Specific Function
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name
SLC15A2
Uniprot ID
Q16348
Uniprot Name
Solute carrier family 15 member 2
Molecular Weight
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:41